z-logo
Premium
Rybelsus: an oral formulation of the GLP ‐1 agonist semaglutide
Author(s) -
Chaplin Steve
Publication year - 2020
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1873
Subject(s) - semaglutide , medicine , agonist , type 2 diabetes , adverse effect , pharmacology , diabetes mellitus , endocrinology , receptor , liraglutide
Rybelsus (semaglutide) is the first GLP‐1 agonist for the treatment of type 2 diabetes to be available as an oral formulation. This article discusses its properties, efficacy and adverse effects.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here